The purpose of the tissue core is to facilitate research on lymphoid malignancies by members of the City of Hope Lymphoma Spore. The core provides services in the following areas;(1) acquisition and banking of fresh and paraffin-fixed tissues of lymphoma patients at City of Hope, including specimens obtained prospectively and retrospectively;(2) comprehensive work-up of lymphoma specimens to ensure correct diagnosis, classification, and detection of minimal residual disease, including immunohistochemical, flow cytometric, molecular pathologic, and cytogenetic studies;(3) performance and assistance in routine histologic processing and immunohistochemical staining of lymphoma tissues, including animal tissue, and preparations from cell lines, as well as specialized histologic services such as preparation of multitumor blocks or tissue microarrays to the specifications of researchers;(4) performance and assistance in Laser Capture microdissections from paraffin or frozen sections to obtain enrichment of specific cell types including isolation of malignant cells for analysis of proteins, RNA and/or DNA content;(5) flow cytometry studies, including complex characterization of lymphoma and host cell populations;(6) cytogenetic studies, including identification of vector-carrying cells and (7) consultation services to other SPORE investigators. In addition a Hematopoietic cell tissue bank has been established to prospectively collect and store fresh bone marrow, peripheral blood and peripheral blood stem cell samples from lymphoma patients undergoing autologous peripheral stem cell transplant (aPBSCT). This bank will support studies in Project 2 evaluating pathogenesis and predictors for t-MDS/AML in lymphoma patients post-aHCT. Samples are obtained pre-transplant and post-transplant at 100 days, 6 months, 1 year, and then annually through 5 years after transplant. Aliquots of the PBSC autograft are also banked. The core also collects and enters follow up outcome information for all patients. The core uses an IRB approved protocol for sample and data collection (see Appendix). The core also follows patients who have received their initial transplant treatment but who are not under current followup at City of Hope, by contacting the treating physician, and if necessary, recalling the patient to the City of Hope for clinical evaluation, blood draw and bone marrow biopsy

Public Health Relevance

The tissue core will facilitate research on lymphoid malignancies by members of the City of Hope Cancer Center by supporting acquisition and banking of tissues from lymphoma patients, providing comprehensive pathological characterization, and assistance with specialized studies specific to the SPORE projects. A Hematopoietic cell tissue bank component of this core will prospectively collect, store and clinically annotate fresh bone marrow and blood cell samples from lymphoma patients undergoing autologous transplant to support studies described in Project 2

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA107399-09
Application #
8731637
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31

Showing the most recent 10 out of 97 publications